Amgen completes Abgenix acquisition
Executive Summary
Amgen has completed its $2.2 bil. acquisition of Abgenix. The deal, inked in December, gives Amgen full ownership of metastatic colorectal cancer treatment panitumumab (1"The Pink Sheet" Dec. 19, 2005, p. 24). The companies announced March 30 that they have completed submission of the rolling panitumumab BLA...
You may also be interested in...
Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA
Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.